Free Trial
→ Elon's next millionaires start October 24? (From Behind the Markets) (Ad)tc pixel Free WNW Stock Alerts

Meiwu Technology (WNW) Competitors

Meiwu Technology logo
$2.17 +0.09 (+4.28%)
As of 11:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

WNW vs. YSG, NUS, NAGE, NATR, and MED

Should you buy Meiwu Technology stock or one of its competitors? Meiwu Technology's main competitors and comparable companies include Yatsen (YSG), Nu Skin Enterprises (NUS), Niagen Bioscience (NAGE), Nature's Sunshine Products (NATR), and Medifast (MED). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "personal care products" industry.

How does Meiwu Technology compare to Yatsen?

Meiwu Technology (NASDAQ:WNW) and Yatsen (NYSE:YSG) are both small-cap consumer staples companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Yatsen has higher revenue and earnings than Meiwu Technology.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Meiwu Technology$7.08M7.74-$18.59MN/AN/A
Yatsen$614.62M0.40-$11.56M-$0.32N/A

Meiwu Technology has a net margin of 0.00% compared to Yatsen's net margin of -4.63%. Meiwu Technology's return on equity of 0.00% beat Yatsen's return on equity.

Company Net Margins Return on Equity Return on Assets
Meiwu TechnologyN/A N/A N/A
Yatsen -4.63%-7.26%-5.42%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Meiwu Technology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Yatsen
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

0.3% of Meiwu Technology shares are owned by institutional investors. 29.0% of Yatsen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Yatsen had 2 more articles in the media than Meiwu Technology. MarketBeat recorded 3 mentions for Yatsen and 1 mentions for Meiwu Technology. Meiwu Technology's average media sentiment score of 1.82 beat Yatsen's score of 0.25 indicating that Meiwu Technology is being referred to more favorably in the media.

Company Overall Sentiment
Meiwu Technology Very Positive
Yatsen Neutral

Meiwu Technology has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market. Comparatively, Yatsen has a beta of -1.71, suggesting that its share price is 271% less volatile than the broader market.

Summary

Meiwu Technology beats Yatsen on 7 of the 11 factors compared between the two stocks.

How does Meiwu Technology compare to Nu Skin Enterprises?

Meiwu Technology (NASDAQ:WNW) and Nu Skin Enterprises (NYSE:NUS) are both small-cap consumer staples companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

In the previous week, Nu Skin Enterprises had 2 more articles in the media than Meiwu Technology. MarketBeat recorded 3 mentions for Nu Skin Enterprises and 1 mentions for Meiwu Technology. Meiwu Technology's average media sentiment score of 1.82 beat Nu Skin Enterprises' score of 0.84 indicating that Meiwu Technology is being referred to more favorably in the media.

Company Overall Sentiment
Meiwu Technology Very Positive
Nu Skin Enterprises Positive

Nu Skin Enterprises has higher revenue and earnings than Meiwu Technology.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Meiwu Technology$7.08M7.74-$18.59MN/AN/A
Nu Skin Enterprises$1.49B0.17$160.20M-$4.47N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Meiwu Technology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Nu Skin Enterprises
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

0.3% of Meiwu Technology shares are owned by institutional investors. Comparatively, 82.8% of Nu Skin Enterprises shares are owned by institutional investors. 2.8% of Nu Skin Enterprises shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Meiwu Technology has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market. Comparatively, Nu Skin Enterprises has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

Meiwu Technology has a net margin of 0.00% compared to Nu Skin Enterprises' net margin of -15.73%. Nu Skin Enterprises' return on equity of 6.58% beat Meiwu Technology's return on equity.

Company Net Margins Return on Equity Return on Assets
Meiwu TechnologyN/A N/A N/A
Nu Skin Enterprises -15.73%6.58%3.63%

Summary

Nu Skin Enterprises beats Meiwu Technology on 9 of the 12 factors compared between the two stocks.

How does Meiwu Technology compare to Niagen Bioscience?

Meiwu Technology (NASDAQ:WNW) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap consumer staples companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

Niagen Bioscience has higher revenue and earnings than Meiwu Technology.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Meiwu Technology$7.08M7.74-$18.59MN/AN/A
Niagen Bioscience$129.42M1.59$17.38M$0.1814.33

Niagen Bioscience has a consensus price target of $10.33, indicating a potential upside of 300.52%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Niagen Bioscience is more favorable than Meiwu Technology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Meiwu Technology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Niagen Bioscience
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.00

0.3% of Meiwu Technology shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 10.0% of Niagen Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Niagen Bioscience has a net margin of 12.39% compared to Meiwu Technology's net margin of 0.00%. Niagen Bioscience's return on equity of 17.95% beat Meiwu Technology's return on equity.

Company Net Margins Return on Equity Return on Assets
Meiwu TechnologyN/A N/A N/A
Niagen Bioscience 12.39%17.95%13.17%

Meiwu Technology has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, Niagen Bioscience has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market.

In the previous week, Niagen Bioscience had 2 more articles in the media than Meiwu Technology. MarketBeat recorded 3 mentions for Niagen Bioscience and 1 mentions for Meiwu Technology. Meiwu Technology's average media sentiment score of 1.82 beat Niagen Bioscience's score of 0.68 indicating that Meiwu Technology is being referred to more favorably in the media.

Company Overall Sentiment
Meiwu Technology Very Positive
Niagen Bioscience Positive

Summary

Niagen Bioscience beats Meiwu Technology on 13 of the 15 factors compared between the two stocks.

How does Meiwu Technology compare to Nature's Sunshine Products?

Meiwu Technology (NASDAQ:WNW) and Nature's Sunshine Products (NASDAQ:NATR) are both small-cap consumer staples companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

0.3% of Meiwu Technology shares are owned by institutional investors. Comparatively, 79.4% of Nature's Sunshine Products shares are owned by institutional investors. 3.1% of Nature's Sunshine Products shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Nature's Sunshine Products has higher revenue and earnings than Meiwu Technology.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Meiwu Technology$7.08M7.74-$18.59MN/AN/A
Nature's Sunshine Products$480.14M0.46$19.52M$1.0112.51

Meiwu Technology has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, Nature's Sunshine Products has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

Nature's Sunshine Products has a net margin of 3.68% compared to Meiwu Technology's net margin of 0.00%. Nature's Sunshine Products' return on equity of 12.88% beat Meiwu Technology's return on equity.

Company Net Margins Return on Equity Return on Assets
Meiwu TechnologyN/A N/A N/A
Nature's Sunshine Products 3.68%12.88%8.17%

In the previous week, Meiwu Technology and Meiwu Technology both had 1 articles in the media. Nature's Sunshine Products' average media sentiment score of 1.86 beat Meiwu Technology's score of 1.82 indicating that Nature's Sunshine Products is being referred to more favorably in the news media.

Company Overall Sentiment
Meiwu Technology Very Positive
Nature's Sunshine Products Very Positive

Nature's Sunshine Products has a consensus target price of $30.50, suggesting a potential upside of 141.30%. Given Nature's Sunshine Products' stronger consensus rating and higher probable upside, analysts clearly believe Nature's Sunshine Products is more favorable than Meiwu Technology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Meiwu Technology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Nature's Sunshine Products
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

Summary

Nature's Sunshine Products beats Meiwu Technology on 11 of the 13 factors compared between the two stocks.

How does Meiwu Technology compare to Medifast?

Medifast (NYSE:MED) and Meiwu Technology (NASDAQ:WNW) are both small-cap consumer staples companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

Meiwu Technology has lower revenue, but higher earnings than Medifast.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medifast$316.93M0.42-$18.67M-$2.33N/A
Meiwu Technology$7.08M7.74-$18.59MN/AN/A

Medifast presently has a consensus price target of $12.00, suggesting a potential downside of 0.34%. Given Medifast's stronger consensus rating and higher probable upside, equities research analysts clearly believe Medifast is more favorable than Meiwu Technology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medifast
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.33
Meiwu Technology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Meiwu Technology has a net margin of 0.00% compared to Medifast's net margin of -8.08%. Meiwu Technology's return on equity of 0.00% beat Medifast's return on equity.

Company Net Margins Return on Equity Return on Assets
Medifast-8.08% -6.69% -5.25%
Meiwu Technology N/A N/A N/A

In the previous week, Medifast had 7 more articles in the media than Meiwu Technology. MarketBeat recorded 8 mentions for Medifast and 1 mentions for Meiwu Technology. Meiwu Technology's average media sentiment score of 1.82 beat Medifast's score of 0.61 indicating that Meiwu Technology is being referred to more favorably in the news media.

Company Overall Sentiment
Medifast Positive
Meiwu Technology Very Positive

Medifast has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Meiwu Technology has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

95.5% of Medifast shares are held by institutional investors. Comparatively, 0.3% of Meiwu Technology shares are held by institutional investors. 3.7% of Medifast shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Medifast and Meiwu Technology tied by winning 7 of the 14 factors compared between the two stocks.

Get Meiwu Technology News Delivered to You Automatically

Sign up to receive the latest news and ratings for WNW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WNW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

WNW vs. The Competition

Export
MetricMeiwu TechnologyPersonal Care Products IndustryConsumer Staples SectorNASDAQ Exchange
Market Cap$55.74M$24.56B$16.77B$12.86B
Dividend YieldN/A5.39%3.28%19.61%
P/E RatioN/A23.4313.9125.22
Price / Sales7.8713.45265,659.5499.68
Price / CashN/A26.4957.3351.56
Price / Book0.013.014.435.96
Net Income-$18.59M$1.13B$844.17M$380.92M
7 Day Performance-1.17%1.33%0.83%-3.33%
1 Month Performance-16.07%-1.89%-1.21%-5.34%
1 Year Performance-98.87%-18.88%9.96%-4.58%

Meiwu Technology Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
WNW
Meiwu Technology
0.5267 of 5 stars		$2.17
+4.3%		N/A-98.9%$56.58M$7.08MN/A92
YSG
Yatsen
0.8662 of 5 stars		$2.66
+0.8%		N/A-68.1%$249.51M$614.62MN/A1,623
NUS
Nu Skin Enterprises
2.2911 of 5 stars		$4.61
-0.1%		N/A-50.9%$224.17M$1.49BN/A2,800
NAGE
Niagen Bioscience
2.2248 of 5 stars		$2.79
flat		$10.33
+270.4%		-65.6%$222.20M$129.42M15.50117
NATR
Nature's Sunshine Products
3.8897 of 5 stars		$12.45
flat		$30.50
+145.0%		-14.9%$219.12M$480.14M12.33806

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:WNW) was last updated on 10/16/2026 by MarketBeat.com Staff.
From Our Partners
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...
Investors Alley | Sponsoredtc pixel
“The crisis that’s emerging now is just the tip of the iceberg,” says Dr. Martin D. Weiss, who has made shocking and accurate predictions for 55 years
Dr. Martin D. Weiss, who predicted the Dot-Com collapse and the failures of Fannie Mae, Bear Stearns, and Lehm...
Weiss Ratings | Sponsoredtc pixel
Trump’s issues shocking Executive Order on U.S. Dollar
Three days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....
Banyan Hill Publishing | Sponsoredtc pixel
Undiscovered Sub-$1 Gold-Silver Royalty Stock Takes Flight
A small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...
Digest Publishing | Sponsoredtc pixel
The oil check Munger called his best deal
Charlie Munger's $1,000 oil investment in 1962 later paid about $70,000 a year, totaling roughly $1 million ov...
The Oxford Club | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
$29.97... or free today
Bill Poulos's report, The Trading For Income System, normally sells for $29.97. Today, it's free through this ...
Profits Run | Sponsoredtc pixel